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Fluticasone/salmeterol reduces 
remodelling and neutrophilic 
inflammation in severe equine 
asthma
Michela Bullone1, Amandine Vargas1, Yvonne Elce1,3, James G. Martin2 & Jean-Pierre Lavoie1
Asthmatic airways are inflamed and undergo remodelling. Inhaled corticosteroids and long-acting 
β2-agonist combinations are more effective than inhaled corticosteroid monotherapy in controlling 
disease exacerbations, but their effect on airway remodelling and inflammation remains ill-defined. 
This study evaluates the contribution of inhaled fluticasone and salmeterol, alone or combined, to the 
reversal of bronchial remodelling and inflammation. Severely asthmatic horses (6 horses/group) were 
treated with fluticasone, salmeterol, fluticasone/salmeterol, or with antigen avoidance for 12 weeks. 
Lung function, central and peripheral airway remodelling, and bronchoalveolar inflammation were 
assessed. Fluticasone/salmeterol and fluticasone monotherapy decreased peripheral airway smooth 
muscle remodelling after 12 weeks (p = 0.007 and p = 0.02, respectively). On average, a 30% decrease 
was observed with both treatments. In central airways, fluticasone/salmeterol reversed extracellular 
matrix remodelling after 12 weeks, both within the lamina propria (decreased thickness, p = 0.005) and 
within the smooth muscle layer (p = 0.004). Only fluticasone/salmeterol decreased bronchoalveolar 
neutrophilia (p = 0.03) to the same extent as antigen avoidance already after 8 weeks. In conclusion, 
this study shows that fluticasone/salmeterol combination decreases extracellular matrix remodelling 
in central airways and intraluminal neutrophilia. Fluticasone/salmeterol and fluticasone monotherapy 
equally reverse peripheral airway smooth muscle remodelling.
Bronchial wall remodelling is a hallmark of asthma resulting from chronic inflammation and 
bronchospasm-induced mechanical stress1, 2. Airway smooth muscle (ASM), whose increase is proportional to 
disease severity3 and caused by cellular hyperplasia and hypertrophy4, is the major contributor to airway obstruc-
tion5. Increased deposition of extracellular matrix (ECM) elements is also a typical feature of severe asthma 
cases6. Multiple studies have focused on central ASM remodelling using samples obtained by endobronchial 
biopsy (EBB). However, EBBs provide partial-thickness samples limited to the carinae of the central airways7, 
while post-mortem studies on entire lungs of severe asthmatics have shown that the most marked alterations 
occur in the peripheral airways, that is, those <2 mm in diameter3, 8.
Peripheral airway dysfunction is associated with poor disease control and with neutrophilic inflammation 
in asthma9, 10. Combining anti-inflammatory and bronchodilating treatments has a synergistic effect on disease 
control even in severe asthmatic patients, which has been ascribed to an enhanced penetration within the bron-
chial tree or to their synergic anti-inflammatory effects11. However, disease control is usually expressed in terms 
of spirometry and patient-reported symptom perception tests, two unreliable indicators of peripheral airway 
dysfunction12. The effectiveness of currently employed asthma treatments at this level on remodelling and inflam-
mation is thus questionable13. Long-term ICS monotherapy effectively reduces the number of peripheral lung 
cells expressing smooth muscle actin in severe asthmatic patients14, but a reduction of parenchymal myofibro-
blasts rather than ASM cells could have accounted for the difference observed. In the same study, long-term ICS 
monotherapy did not decrease the quantity of collagen in peripheral lung samples and a different regulation 
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of remodelling reversal was reported centrally and peripherally. Ultimately, whether ICS/LABA combination 
can reverse established remodelling in peripheral asthmatic airways and whether this is reflected by significant 
changes in the central airways remains undetermined.
Indirect small airway assessment in asthma is limited by the paucity of diagnostic tools available15. Direct 
sampling is challenging and requires invasive procedures16, whose implementation in human studies is limited 
by ethical considerations. For these reasons, animal models represent essential tools for investigating small air-
way pathophysiology and response to treatment in asthma. Adult horses exposed to barn antigens can develop 
severe equine asthma (previously known as “heaves”), a disease characterized by airway remodelling and neutro-
philic inflammation17, 18. Equine lung samples and endobronchial biopsies can be easily harvested, which makes 
asthmatic horses ideal models for the translational study of asthma-associated remodelling of the peripheral 
and central airways17, 19. This study was designed for evaluating the specific contribution of anti-inflammatory 
and bronchodilator treatments, alone or combined, to lung function, inflammation control, and remodelling 
reversal in the equine model of neutrophilic asthma. We hypothesized that combination therapy with ICS/LABA 
enhances peripheral remodelling reversal by enhanced anti-inflammatory effect.
Results
Animals. Table 1 reports physiological details of the horses studied. Haematological results obtained at base-
line were within normal ranges, excluding the possibility of concomitant respiratory infections in the horses stud-
ied. In study I, 2/13 horses had slightly increased blood fibrinogen (5 g/L, reference range: 2–4 g/L). In study II, 
only 1 horse had fibrinogen at 5 g/L. Increased blood fibrinogen concentration is reported in asthmatic horses20.
Lung function. At baseline, all horses had severe airway obstruction as demonstrated by their increased 
pulmonary resistance and elastance compared to normal values (Fig. 1a,c). Fluticasone/salmeterol normalized 
pulmonary resistance and elastance from week 1 to 12. Antigen avoidance induced a similar rapid decrease in 
elastance, while resistance decreased only after 4 weeks and remained above normal values in 4/7 horses at 12 
weeks (Fig. 1a). Fluticasone and salmeterol administered separately both decreased resistance and elastance after 
1 week of treatment, which was maintained until week 12 only by fluticasone. The effect of salmeterol on pulmo-
nary function was partly lost in 3 out of 6 horses after 8 weeks of treatment. It was only temporarily restored by a 
single dose of oral dexamethasone (0.06 mg/kg) administered at the end of week 821 (Fig. 1c). At week 12, residual 
bronchoconstriction was detected in antigen avoidance and salmeterol-treated horses (Fig. 1b,d).
Airway luminal inflammation. Antigen exposure induced BAL fluid (BALF) neutrophilia (>20%) in all 
groups at baseline. Antigen avoidance reduced neutrophilia after 1 week, but only 3/7 horses had normal values 
(<5%) by week 12. Despite ongoing antigen exposure, fluticasone/salmeterol reduced BALF neutrophilia starting 
from week 8, with 3/6 horses reaching normal values at week 12 (Fig. 2a). Fluticasone and salmeterol monother-
apies were ineffective (Fig. 2b).
Peripheral remodelling. Peripheral remodelling was assessed in 10 ± 4 airways/horse/time during study 
I and 10 ± 3 during study II (range: 3–25). Average airway Pi was 811 ± 221 μm in study I and 883 ± 456 μm in 
study II (range: 160–1996 μm). It was similar between groups and time points studied.
At baseline, the ASM mass was similar in all treatment groups (Fig. 3a,b). It was comparable to previously 
reported values of ASM remodelling in asthmatic horses22–24. In the peripheral ASM layer, ECM was mainly 
comprised of elastin with rare collagen deposition (Supplementary Table S1). Overall, peripheral ASM mass was 
greater in asthmatic horses with a history of RL > 3 cmH2O/L/sec, independently of treatment or time (p = 0.03, 
Supplementary Fig. S1). On average, fluticasone/salmeterol reduced ASM mass by 27% (range: 3–45%) at 12 
weeks when compared to baseline (p = 0.007, Fig. 3a). Antigen avoidance had no effect. Inhaled fluticasone, but 
not salmeterol, reversed ASM remodelling at 12 weeks (p = 0.02, average reduction 33.6%, range: 4–62%, Fig. 3b) 
to the same extent observed with fluticasone/salmeterol.
Study I Study II
Antigen 
avoidance
Fluticasone/
Salmeterol p value Fluticasone Salmeterol p value
N 7* 6 6 6
Age [years] 18.5 ± 6.3 15.3 ± 4.5 0.36 14.3 ± 5.6 15.2 ± 3.7 0.66
Weight [kg] 487 ± 91 544 ± 115 0.34 513 ± 57 543 ± 74 0.82
Sex [f/m] 4/3 5/1 0.56 5/1 3/3 0.54
Disease 
duration† [years] 4.6 ± 2.6 3.3 ± 1.4 0.42 4.5 ± 3.5 4.0 ± 1.3 0.69
Disease severity 
[RL < 3 / RL > 3]¶
3/4 5/1 0.56 3/3 3/3 1
Table 1. Horses’ description. Eight months elapsed between study I and II. Seven out of 17 horses participated 
in both studies, equally distributed between groups. *One horse in the antigen avoidance group underwent all 
sampling except peripheral lung biopsies. †For horses with unknown history, disease duration was estimated 
as starting one year before the moment they joined the research herd, a possible underestimation. ¶Disease 
severity was determined based on the horse clinical history and lung function data, with horses reaching at least 
once in the observation period in our research herd prior or during the study a respiratory resistance (RL) > 3 
cmH2O/L/sec during disease exacerbations classed as those with increased disease severity.
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The number of myocyte nuclei/Pi2 remained unvaried along the study period in all groups (Fig. 3e,f). Myocyte 
size (Fig. 3c) and ECM fraction of ASM (Fig. 4d) were decreased by fluticasone/salmeterol, contributing respec-
tively to 80% and 20% of the observed reduction of peripheral ASM mass at 12 weeks. Antigen avoidance only 
transiently decreased myocyte size at 4 weeks (Fig. 3c). Fluticasone did not affect myocyte size or ECM fraction 
of the ASM layer (Figs 3d and 4e). The normalized quantity of ECM in the lamina propria of peripheral airways 
was unaffected by 12 weeks of either treatment studied (Fig. 4b,c). Additional data on peripheral ECM fraction 
remodelling reversal are provided online (Supplementary Fig. S2).
In both studies, ASM mass correlated with myocyte nuclei/Pi2 at baseline (r = 0.92, p < 0.0001 in study I; 
r = 0.87, p = 0.0003 in study II) and after 12 weeks (r = 0.87, p = 0.0002 in study I; r = 0.8, p = 0.001 in study II), 
whereas after 4 weeks of treatment the correlation was significant only for fluticasone-treated horses (r = 0.85, 
p = 0.03). Values of ASM mass at baseline and at 12 weeks were correlated in fluticasone/salmeterol (r = 0.84, 
p = 0.03), antigen avoidance (r = 0.85, p = 0.03), and salmeterol (r = 0.81, p = 0.048), but not in fluticasone-treated 
horses (r = −0.07, p = 0.9).
Central remodelling. On average, 5 EBBs/horse/time were analysed in both studies (range: 3–6), of which 
3.5 ± 1.8 considered of good-to-optimal quality in study I and 3.8 ± 1.4 in study II, with no differences between 
groups and time points studied.
At baseline, EBUS yielded values similar to those previously published using this technique in asthmatic 
horses, indicating increased ASM mass25. Only fluticasone/salmeterol reduced submucosal remodelling as indi-
cated by EBUS at 12 weeks (Fig. 5b), concomitantly with a reduction of the ECM fraction of central ASM (Fig. 6c) 
and of the lamina propria thickness, which reacquired values similar to those reported in healthy horses19 
(Fig. 6d). This change was accompanied by a concomitant decrease in ASM area within endobronchial biopsies 
(Fig. 6a). Fluticasone monotherapy did not affect ASM area, ASM composition or lamina propria thickness. 
Salmeterol treatment did not alter ASM area (Fig. 6e), but it tended to reduce the ECM fraction of central ASM 
at 12 weeks (Fig. 6g) and partially decreased lamina propria thickness at 4 and 8 weeks, while its effect was lost at 
12 weeks (Fig. 6h). Antigen avoidance did not affect central ECM. Further details on remodelling reversal of the 
central ECM fraction are available online (Supplementary Fig. S3). Myocytes of all groups reached a similar size at 
4 weeks of treatment, and maintained this size until week 12. Myocyte size was significantly reduced by all treat-
ments by week 4, but the effect was significant only for fluticasone and antigen avoidance treatment (Fig. 6b,f).
Figure 1. Pulmonary function and bronchoreversibility tests performed in study I (a,b) and II (c,d). 
Bronchodilator response was evaluated before and 30 minutes after the administration of inhaled albuterol 
500 μg (b) or intravenous N-butyl-scopolamine 0.03 mg/kg (d) to detect residual airway obstruction. Values 
are expressed as means ± S.E.M. Dashed lines represent normal threshold in healthy horses. RL: pulmonary 
resistance; EL: pulmonary elastance; ΔPL: swing in transpulmonary pressure. ‡different from baseline of the 
same group for fluticasone/salmeterol (p < 0.0001), ¤different from baseline for antigen avoidance (p < 0.05), 
*different from baseline for fluticasone (p < 0.0001), #different from baseline for salmeterol (p < 0.0001), 
§difference between groups at the time point indicated (p < 0.05).
www.nature.com/scientificreports/
4Scientific REPoRTs | 7: 8843  | DOI:10.1038/s41598-017-09414-8
Comparison between central and peripheral ASM. EBUS-assessed central ASM remodelling nega-
tively correlated with endobronchial biopsy ASM area at baseline in all horses (r = −0.70, p = 0.01) and at 12 
weeks only in fluticasone/salmeterol-treated horses (r = −0.85, p = 0.06). A negative correlation was expected 
as an increased thickness of the lamina propria could prevent a deep sampling within the smooth muscle layer19. 
EBUS-assessed central ASM remodelling also correlated with peripheral ASM mass (ASM/Pi2) at baseline in all 
horses (Fig. 5c) and at 12 weeks only in fluticasone/salmeterol-treated horses (r = 0.88, p = 0.03).
ASM bundle composition differed in peripheral and central airways, independently of treatment or time. 
Overall, ECM fraction was higher centrally than peripherally (p = 0.0002). Within the ECM fraction, collagen 
predominated centrally while elastin prevailed peripherally (p < 0.0001, Supplementary Table S1). A linear rela-
tionship was observed in study I between central and peripheral myocyte size (p = 0.007), independently of treat-
ment or time.
Disease evolution across the study period in horses participating in both studies. Seven horses 
participated in both studies, equally distributed between groups. In order to assess whether this introduced any 
bias in our analysis, we compared the baseline values of these 7 horses (veterans) during the 2 studies, as well as 
their baseline value during study II compared to the baseline values of the 5 remaining horses newly included in 
the study (recruits). Baseline lung function was similar in these subjects during both projects, and it was similar 
in veterans and recruits at baseline of study II (Supplementary Table S2).
Peripheral ASM and ECM mass (ASM/Pi2 and ECM/Pi2, respectively) of veterans were similar at baseline of 
both studies, indicating the absence of a cross-over effect of study I over study II. Also, ASM/Pi2 and ECM/Pi2 
values at baseline of study II were similar in recruits and veterans (p = 0.5 and p = 0.2, respectively). In central 
airways, the ECM thickness of veterans was similar in study I and study II (p = 0.5) and between recruits and 
veterans at baseline of study II (p = 0.3). Data are provided in Supplementary Table S3. ASM layer composition 
of central and peripheral airways did not vary across the studies in veteran horses (p = 1 and p = 0.2, respec-
tively) and it was similar between veterans and recruits at baseline of study II (p = 0.2 and p = 0.9, respectively, 
Supplementary Fig. S4).
Discussion
Airway remodelling is a hallmark of asthma affecting both the ASM and the ECM of peripheral and central 
bronchi, and its reversibility following treatment is a matter of debate1. The specific anti-remodelling effects of 
currently employed asthma treatments on the peripheral airways are largely unknown. Our study examined 
Figure 2. Bronchoalveolar lavage fluid cytology of study I (a) and II (b). Values are expressed as means ± S.E.M. 
*different from baseline of the same group (p < 0.05); ‡Difference between groups at the time point indicated 
(p < 0.05). BALF: bronchoalveolar lavage fluid cytology.
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reversibility of peripheral ASM and ECM airway remodelling following administration of fluticasone, salmeterol, 
or their combination in an equine model of neutrophilic asthma. We also investigated the effects of these drugs 
on central airways in order to understand whether any aspect of central remodelling is indicative of the structural 
changes occurring more distally within the bronchial tree. Notably, in order to outline the specific contribution of 
mechanical stress to bronchial remodelling we assessed the effects of salmeterol monotherapy in our study, which 
is precluded in human asthma due to safety concerns12. Our results indicate that the reversal of peripheral ASM 
remodelling is mainly influenced by corticosteroid-mediated mechanisms and that it is not accompanied by the 
reversal of airway luminal inflammation. Based on our data, the number and size of ASM cells are not affected 
by mechanical stress acting on the airways. Bronchospasm inhibition however reduced the quantity of bronchial 
ECM, both within and outside the ASM layer, with a greater effect observed centrally than peripherally.
Severe neutrophilic asthma represents an uncommon phenotype of the disease associated with peripheral air-
way dysfunction10. However, no studies have specifically described the structural changes affecting the peripheral 
airways of this subtype of patients or their response to treatment to date. In this perspective, severe equine asthma 
represents a unique model to study unknown aspect of the disease. Such as severe neutrophilic asthmatics, horses 
affected by severe equine asthma display bronchoalveolar neutrophilia and they are poorly responsive to low-dose 
ICS as reliever therapy, while they are effectively controlled with high-dose ICS or oral corticosteroids24. In the 
present study we have administered high-dose fluticasone or combined fluticasone/salmeterol as both relief and 
maintenance therapy, in order to assess whether these symptomatically efficacious treatments differed in terms of 
airway remodelling reversal and inflammation control. The molecular basis of the synergistic anti-inflammatory 
effect of ICS/LABA combinations has been documented in vitro11, and some studies suggest that LABA may 
Figure 3. Peripheral airway smooth muscle remodelling. The corrected quantity of ASM, as well as ASM cell 
hypertrophy and hyperplasia were assessed by histology in study I (a,c, and e, respectively) and II (b,d, and 
f). Each symbol represents one horse (mean value of multiple measures performed). *Different from baseline 
of the same group (p < 0.05); §difference between groups at the time point indicated (p < 0.05). ASM: airway 
smooth muscle; Pi: internal perimeter of the airway. (g,h) Representative examples of the cumulative frequency 
distribution of peripheral ASM remodelling (ASM/Pi2) in one horse treated with fluticasone/salmeterol (g: 
n = 16 airways/time) and another one treated with antigen avoidance (h: n = 19 airways/time). Dashed lines 
identify median values.
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selectively inhibit IL-8 concentration in BAL fluid and neutrophil influx into asthmatic airways in vivo26–28. As 
activated neutrophils secrete chemicals able to induce tissue damage and involved in airway remodelling29, an 
efficacious control of airway neutrophilia could enhance airway remodelling reversal. Our findings support the 
potential of fluticasone/salmeterol to reduce pulmonary neutrophilia in asthma. Assuming that neutrophilic 
inflammation control can be maintained over time by fluticasone/salmeterol, further studies extended to >3 
months will have to understand whether it can also potentiate ASM remodelling reversal.
ASM is the main determinant of airway obstruction in asthma5. A marked increased in peripheral ASM mass 
has been associated with the more severe forms of the disease3. Our study is in agreement with this finding as 
peripheral ASM mass increased with disease severity at baseline. Moreover, our results indicate that chronically 
established peripheral ASM remodelling is reversible in vivo, although only partly, by 3 months of ICS treat-
ment. The same degree of reversibility (~30% reduction) has been reported in asthmatic horses after 6 and 12 
months of ICS treatment24, suggesting that components of peripheral ASM remodelling, once established, may 
be irreversible. This may be due to «premodelling» (congenital remodelling preceding symptoms)30 or to a dis-
proportion between the detrimental effects of inflammation during the establishment of remodelling and the 
beneficial effects of inflammation control during remodelling reversal. A mathematical model of ASM growth 
in disease has shown that years of complete inflammation control may be required to counterbalance the ASM 
mass increase caused by a short period of severe airway inflammation31, whereas persistent mild-degree inflam-
mation, as observed in asthma despite treatment32, 33, would freeze ASM mass in its remodeled state, preventing 
reversal. In either way, both the increased ASM and uncontrolled small airway dysfunction reported in asth-
matic patients considered adequately treated4, 8 are in agreement with our findings. The absence of a significant 
decrease in ASM mass with salmeterol and the similar effect observed with fluticasone and fluticasone/salmeterol 
treatment on peripheral ASM remodelling reversal suggest that a corticosteroid (anti-inflammatory) treatment 
is necessary to reverse the increased ASM mass in asthma while mechanical stress per se is unlikely to influence 
ASM cell number and size. Fluticasone could have reduced the ASM mass via direct and indirect action on ASM 
cells. Corticosteroid administration suppresses ASM cell proliferation34 and modulates the genetic expression 
profile of ASM cells in asthmatic patients35 by increasing myocardin expression, a marker of ASM cells differen-
tiation and contractility. In agreement with these findings, myocardin expression decreases in bronchial biopsies 
obtained after antigen challenge in asthmatic horses36. Recent data also support a neutrophil-mediated increase 
of ASM cell proliferation in severe equine asthma37. For this reason, the expected inhibitory effect of ICS on 
pulmonary neutrophilia could have contributed to the observed reduction in peripheral ASM mass in our study. 
Counterintuitively, however, airway luminal neutrophilia decreased only after 8 weeks of fluticasone/salmeterol 
treatment, while fluticasone monotherapy was ineffective. Although an increased risk of pneumonia is reported 
in asthmatic patients treated with inhaled fluticasone38, our horses did not show signs of pneumonia during the 
study period (fever, lethargy, pleurodynia), excluding the hypothesis that the blunted response observed in the 
Figure 4. Peripheral ECM remodelling. (a) Representative image of a small airway of an asthmatic horse 
in which smooth muscle stains dark pink, collagen stains yellow, and elastin stains black (Russell-Movat 
pentachrome staining). Scale bar: 50 μm. (b,c) Corrected area of total ECM within the lamina propria of small 
airways of the horses participating in study I (b) and II (b). Each symbol represents one horse (mean value of 
multiple measures performed). (d-e) ECM fraction within the peripheral ASM layer of horses participating 
in study I (d) and II (e). *Different from baseline of the same group (p < 0.05). ECM: extracellular matrix; EF: 
elastic fibers; Pi: internal perimeter.
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fluticasone group could have been associated with infection. Further studies are warranted to clarify whether 
luminal neutrophilia reliably reflects peripheral bronchial wall and parenchymal inflammation in severe equine 
asthma.
Increased or altered ECM deposition occurs in the submucosa of asthmatic airways and contributes to airway 
remodelling in asthma1. Scientific evidence sustains a role, possibly synergic, for both inflammation and mechan-
ical stress in the regulation of ECM deposition within the airways2, 39, but little is known concerning its reversal 
following treatment. We observed that the inhibition of ECM deposition differed across bronchial structures 
(lamina propria vs. ASM) and sites (peripheral vs. central). Overall, our data suggest that regulation of ECM 
deposition in severe equine asthma is mainly regulated by β-adrenergic-mediated mechanisms, although ICS 
could also contribute to it. Within the ASM layer, ECM deposition was reversed both peripherally and centrally 
Figure 5. Assessment of central airway remodelling with EBUS. (a) Representative image of a central airway 
obtained with EBUS in a horse with asthma. Thin white arrows indicate the 3 hyperechoic layers of the 
bronchial wall representing, from the airway lumen going outwards, the bronchial epithelium, the inner, and the 
outer borders of the bronchial cartilage. The distance between the thick yellow arrows illustrates the thickness 
of L2. (b) EBUS-assessed central airway remodelling in study I. (c) Correlation between EBUS-assessed 
central airway remodelling and peripheral ASM remodelling assessed at histology at baseline (T0) in study 
I. Each symbol represents one horse (mean value of multiple measures performed). L2: second layer; EBUS: 
endobronchial ultrasound; ASM: airway smooth muscle; Pi: internal perimeter. *Different from baseline of the 
same group (p < 0.05); §difference between groups at the time point indicated (p < 0.05).
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by fluticasone/salmeterol. Salmeterol monotherapy also reduced the amount of collagen at both levels, although 
to a lesser degree than that observed with fluticasone/salmeterol. Contrarily, within the lamina propria, ECM 
deposition decreased only in central airways. A complete reversal was observed with fluticasone/salmeterol, while 
fluticasone and salmeterol monotherapies showed either a partial or transient effect, respectively. Intrinsic dif-
ferences between central and peripheral fibroblasts40 may explain our findings. Alternatively, the presence of 
different inflammatory environments or mechanical forces acting on the lamina propria of central and peripheral 
airways, or the lower peripheral deposition of inhaled drugs could also have contributed, as high-doses of ICS 
are needed to reduce ECM deposition within the lamina propria in asthmatic patients41. In summary, our results 
sustain a significant effect of mechanical stress inhibition on ECM deposition at all levels of the bronchial tree, 
which is enhanced when concomitant corticosteroid-regulated mechanisms are activated. They also suggest that 
ECM deposition in the lamina propria of peripheral airways is less responsive to treatment than that of the central 
airways in neutrophilic asthma, although the reasons of these findings remain to be elucidated.
Different ECM components can modulate the mechanical behaviour of the airways during bronchoconstric-
tion42. For this reason, there is growing interest in the composition of the ASM layer in asthma. Nevertheless, the 
composition of the ASM layer and its variability along the human bronchial tree has been investigated only in 
a limited number studies. In asthmatic horses, the ECM fraction of the ASM layer is mainly made up of elastin 
peripherally and of collagen centrally, which reflects the mechanical properties of the lungs. This is in agreement 
with a human study showing that the fractional area of the elastic fibers within the ASM is higher in the small 
than in the large airways of nonfatal asthmatics43. James and colleagues reported that, on average, 18–20% of the 
ASM layer is occupied by ECM both in central and peripheral airways of asthmatic patients4, which is also in line 
with our results. Yick and colleagues reported values of elastin and collagen fraction in the central airways of mild 
asthmatic subjects of 1–3% and 10–30%, respectively44, which closely resemble those we observed in the central 
airways of asthmatic horses. Finally, Araujo and colleagues reported an increased elastin fraction in central and 
peripheral ASM of fatal asthmatics (14–17%) compared to non-fatal asthmatics (2–3%) and healthy patients 
(7–8%)43. Overall, asthmatic horses appear to have elastin fractions in ASM similar to those reported in periph-
eral airways of fatal asthmatics and in central airways of mild asthmatics. Similarly, the collagen fraction observed 
in equine central airways is comparable to that observed in mild to moderate asthmatics. However, the collagen 
fraction of ASM in peripheral airways appears to be significantly lower in horses compared to human asthmatics. 
Whether this is due to intrinsic differences in the ASM cells or in the airway fibroblasts lying within the bronchial 
matrix, as shown in asthma45, or in both these cell-types, remains to be clarified. Besides providing evidence that 
a structural dichotomy exists between central and peripheral ASM composition in asthmatic horses, our results 
also highlight that it can be modulated by pharmacological treatment. Specifically, the combined administration 
of fluticasone and salmeterol is effective at reducing the elastin and collagen fraction of ASM in the peripheral 
and central airways, respectively. Of note, the collagen fraction of peripheral airways was also decreased in all 
subjects with fluticasone/salmeterol treatment (p = 0.04 with paired t-test) but it was not statistically signifi-
cant after Bonferroni correction for multiple comparison. Interestingly, this effect was also observed in horses 
treated with salmeterol monotherapy but not in horses treated with fluticasone monotherapy, suggesting that 
β2-adrenoceptor-mediated mechanisms are likely to be involved. Similarly to our results, asthmatic patients who 
received regularly corticosteroids in addition to short-acting bronchodilators had a reduced quantity of elastin 
in their large and small airways43. Also, an increased ECM deposition has been reported in the central ASM layer 
Figure 6. Central ASM and ECM remodelling. ASM area, myocyte size, ECM fraction of the ASM, and 
thickness of the ECM in the lamina propria were assessed in study I (a–d) and II (e–h). Each symbol represents 
one horse (mean value of multiple measures performed). Dashed line in panels d and h corresponds to the 
mean thickness of ECM reported in healthy horses in a previous study19. *Different from baseline of the same 
group (p < 0.05); ♮p = 0.05 from baseline of the same group. ASM: airway smooth muscle; ECM: extracellular 
matrix.
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of moderate asthmatics compared to severe asthmatics and control, which can be the consequence of the higher 
corticosteroid and bronchodilator regimen implemented in the latter group46. In vitro evidence exists supporting 
the ability of β2-adrenoceptor agonists at reducing pro-fibrotic events in human airways47, 48.
Peripheral airway assessment is rarely implemented in human respiratory research due to ethical considera-
tions, as it requires invasive procedures to be performed16. Indirect evaluation of peripheral airway dysfunction 
in asthma is limited by the paucity of diagnostic tools available, and the need expressed by the respiratory com-
munity to develop non-invasive (or less invasive) markers of peripheral airway structure and function remains 
currently unmet15. One of the goals of our study was to assess whether elements of peripheral airway remodelling 
or their reversal could be predicted based on remodelling affecting the central airways. Our results suggest that, 
when EBUS is used to assess central airway remodelling and it is assumed that changes observed by EBUS pro-
portionately reflect ASM dynamics25, the onset and extent of ASM reversal observed centrally reflects what occurs 
in the peripheral airways. Although EBUS is a complex procedure to be implemented, it is non-invasive and our 
data support its use for indirect peripheral airway structure assessment. Further studies, however, will have to 
confirm our findings. Despite a linear relationship was observed between myocyte size of central and peripheral 
ASM cells in Study I, it was not detected in Study II, suggesting it is not a constant finding.
During our study, salmeterol-treated horses experienced disease exacerbations after 8 weeks of treatment. 
Based on the results of a meta-analysis including more than 100 trials49, regular β-agonists use is now discouraged 
in people12 as it worsens asthma control and increases mortality. Our observations are in agreement with this 
finding. Despite effectively bronchodilating the airways even when administered for extended periods of time 
(especially partial agonists such as salmeterol), β2-agonists increase airway responsiveness50, 51. Moreover, these 
drugs induce vasodilation as well as bronchodilation, which could facilitate the influx of inflammatory cells into 
the airways or participate in airway wall thickening while masking clinical symptoms52. Based on our data, we 
cannot conclude about the effect of the treatments studied on the number of inflammatory cells into the airways, 
as the volume of the bronchoalveolar lavage recovered is variable and related to the degree of collapse of the air-
ways in horses. However, horses treated with salmeterol monotherapy showed a blunted bronchodilator response 
to salmeterol treatment starting from week 9, which did not respond to a single administration of dexametha-
sone and thus which probably was not due to the occurrence of tachyphylaxis in ASM cells21. Also, remodelling 
parameters were unchanged at week 12 compared to the previous time points studied, suggesting that the reduced 
disease control was not related to a worsening of airway remodelling. Based on these observations, we postulate 
that the reduced disease control observed in horses might have been caused by an increased responsiveness of 
ASM cells to the antigenic stimulation. Alternatively, β2-agonist-induced goblet cell hyperplasia is described in 
murine models of asthma53, 54. The same mechanism, if proven to occur in asthmatic horses, could contribute to 
the increased airway obstruction we observed in our animals.
Several studies supports the fact that lung function decline is related to exacerbation frequencies55–57 and that 
it can be reduced by long term corticosteroid administration58, 59 in human asthmatic patients, while no similar 
data are available for asthmatic horses. As 7/18 animals participated in both studies, we compared the baseline 
data of these animals in the two studies in order to exclude the possibility of any cross-over effect. We found no 
significant differences in the lung function or remodelling parameters assessed. This finding is meaningful for 
two reasons: firstly, it suggests that established airway remodelling does not significantly worsen over a period 
of 1 year (3 months duration of study I + 8 months elapsing between study I and study II + 1 month of antigen 
exposure of study II before baseline values were collected), which is reflected by the stable lung function data in 
the same subjects. Secondly, it represents the first evidence of a “return to the original pathological remodelling” 
when treatment is stopped and horses are re-exposed to environmental triggers of asthma exacerbations. These 
observations, joined to the fact that the same degree of peripheral ASM remodelling (increased about threefold 
compared to control animals) was observed in asthmatic horses participating in different studies22, 23, suggest that 
the effect of chronic inflammation on ASM remodelling reaches a plateau early in disease development, and that 
such inflammatory milieu, if not constantly hindered, can quickly reactivate peripheral ASM and re-establish 
airway remodelling. Our data indicates that the significant 30% reduction observed in ASM mass after 12 weeks 
of ICS treatment is not maintained in time after the treatment is stopped, and such effect is completely lost after 
8 months of ICS withdrawal. Further studies are required to better elucidate the kinetics of remodelling reestab-
lishment after treatment withdrawal.
In conclusion, this study shows that at least 3 months are required to significantly decrease ASM mass in the 
equine model of neutrophilic asthma when fluticasone is administered at high dosage. Salmeterol add-on therapy 
allowed luminal neutrophilic inflammation control but did not enhance the reversibility of peripheral remodel-
ling over fluticasone monotherapy. The mechanisms by which fluticasone reduces peripheral ASM mass remain 
to be elucidated although our data suggest that a reduction in ASM cell size is likely to be implemented before 
ASM cell number is reduced. The reduction of ECM deposition within the ASM layer appears as a β-adrenergic 
mediated mechanism. In central airways, fluticasone/salmeterol completely reversed ECM remodelling, while 
their effect was blunted when administered as monotherapies. Overall, the observed effect of ICS/LABA on ECM 
remodelling and luminal inflammation could contribute to the improved clinical response observed in severe 
asthmatics; however, their similar effect on peripheral ASM may explain why complete disease remission is not 
achieved in these patients.
Methods
Experimental design. Experiments were performed on 2 consecutive years. Eighteen asthmatic horses were 
studied. They underwent 5 weeks of antigen exposure consisting of stabling and hay-feeding in order to induce 
clinical exacerbation of the disease. Complete blood counts and blood biochemistry profiles were performed 
at baseline (T0) in order to exclude any respiratory infection. They were then treated for 12 weeks with one of 
four treatments. During the first year of experimentations (study I), horses were either moved to a low-antigenic 
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environment (pasture, considered the gold standard approach for controlling airway inflammation in heaves24, 
n = 7) or administered inhaled fluticasone/salmeterol (Advair® 250 HFA MDI, GlaxoSmithKline, 2500/250 μg 
q12 h, n = 6). During the second year (study II), horses were administered either inhaled fluticasone (Flovent® 
HFA MDI, GlaxoSmithKline, 2500 μg q12 h, n = 6) or salmeterol (Sigma-Aldrich, 250 μg q8 h, n = 6). Seven 
horses participated in both experimental sessions. All drug dosages have previously been validated for use in 
severe equine asthma24, 60. Horses receiving pharmacological treatments were kept in the offending environment 
(stable and hay diet) while treated. Pulmonary function, bronchoalveolar lavage (BAL), EBBs, peripheral lung 
biopsies, and endobronchial ultrasound (EBUS) were performed as described in Fig. 7. All the experiments 
described were conducted in compliance with the guidelines of the Canadian Council on Animal Care. Ethical 
reasons also prevented the inclusion of a placebo group. The study protocol was approved by the local Ethics 
Committee (Rech-1324).
Drug administration. Fluticasone/salmeterol combination and fluticasone alone were administered by 
means of an equine aerosol chamber (AeroHippus, Trudell Medical International), following the manufacturer 
instructions. Salmeterol powder was solubilized in sterile PBS at a concentration of 250 μg/ml, using Tween20 
(Sigma-Aldrich) to facilitate solubility54. The dose of salmeterol administered (250 μg q8 h) was supported by 
previous data60 and by the results of preliminary tests we realized on asthmatic horses showing a significant bron-
chodilator effect persisting up to 6 hours post administration (Supplementary Fig. S5). Salmeterol was adminis-
tered using a face-tight mask equipped with a mobile ultrasonic nebulizer (SaHoMa, NEBU-TEC International, 
Germany).
Lung function. Lung function was assessed as previously described61. Briefly, transpulmonary pressure was 
estimated by means of an oesophageal balloon and respiratory flows detected using a heated pneumotachograph 
connected to a face-tight mask placed on the horse’s nose. Pulmonary resistance and reactance were then com-
puted using dedicated software (Labdat/Anadat program on MS-DOS, and flexiWare software, SCIREQ, Canada). 
A single-compartment linear model of the lung was employed, expressed as: PL = (EL × VT) + (RL× V) + k, where 
PL: transpulmonary pressure, EL: pulmonary elastance, VT: tidal volume, RL: pulmonary resistance, V: respiratory 
flow, and k: transpulmonary end-expiratory pressure. Residual bronchoconstriction was assessed at the end of the 
treatment period using inhaled albuterol (500 μg, in study I) or N-butyl-scopolamine bromide (0.3 mg/kg IV, in 
study II) at dosages previously demonstrated to be effective in asthmatic horses62, 63. In order to assess residual 
bronchoconstriction, lung mechanics were repeated before and 20 to 30 minutes after bronchodilator 
administration.
Bronchoscopy. Bronchoscopies were performed on standing sedated horses (detomidine/butorphanol 
administered IV at 0.015/0.015 mg/kg). BALF was first obtained from a lung, randomly chosen for each animal 
at baseline and then systemically changed at every time point, stored on ice and processed within 2 hours for 
cytology assessment64. Differential cell counts were performed on a minimum of 400 cells on Wright-Giemsa 
stained cytospins of non-filtered BALF aliquots of 400 μm each. When cell density was too high to allow reliable 
counting, cytospins of 200 μm aliquots were prepared. Six to eight EBBs were obtained from the contralateral lung 
as previously described19, fixed in PFA for 24 hours, and paraffin-embedded. Care was taken to avoid biopsying 
twice the same bronchial bifurcation. EBUS images were obtained from the lung used for the BAL procedure 
following a protocol previously developed and validated in our laboratory25. Briefly, a 30 MHz radial miniprobe 
was employed (UM-S30-25R, Olympus,Richmond Hill, ON, Canada) with its dedicated balloon-ended sheath 
(MH-246R, Olympus,Richmond Hill, ON, Canada). Three to 5 images per airway were obtained from 8 to 10 
bronchi ranging from 4 to 12 mm in diameter. The area of the second layer (L2) and the internal perimeter (Pi) 
were measured on digital images by the same observer blinded to the subject ID and L2 area/Pi2 calculated.
Thoracoscopy. Thoracoscopies were performed on standing sedated horses (detomidine/butorphanol 
0.015/0.015 mg/kg IV), restrained in a stock. Large peripheral lung biopsies (>5 cm3) were obtained by means 
Figure 7. Study design. Grey background indicates antigen exposure. BAL: bronchoalveolar lavage; EBB: 
endobronchial biopsies; EBUS: endobronchial ultrasound.
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of a cautery device (Ligasure, Covidien) and endoscopic staplers (Endo GIA, Covidien) as described in previous 
reports65, 66, fixed in PFA for 72 hours, and paraffin-embedded.
Histomorphometry. Morphometry was performed on Russell-Movat-stained tissues67 using ImageJ (NIH, 
Bethesda, USA) and newCAST (Visiopharm, Hoersholm, Denmark). Preliminary studies comparing histomor-
phometry results obtained on Russel-Movat trichrome and immunostained tissues revealed a good agreement 
between the two methods (Supplementary Fig. S6). EBBs of good to optimal quality19 and peripheral bronchi <2 
mm in diameter with a major to minor axis ratio < 1.5, ASM surrounding at least 70% of their circumference, and 
intact epithelium were studied at 40x magnification. In peripheral lung biopsies, the area occupied by ASM and 
extracellular matrix (ECM) was measured manually tracing the border of the ASM bundles (for ASM) and tracing 
the area enclosed between the basal membrane and the ASM layer (for ECM). This was possible as in peripheral 
airways this tissue is dense and clearly stains yellow (collagen), blue (proteoglycans), or black (elastic fibers, EF)
(Fig. 4a). The area occupied by EF was estimated by point counting, using a grid superimposed to the image 
where each point corresponded to an area of 88 μm2. Total EF area was then calculated as (n points × 88 μm2). 
The number of myocyte nuclei within the entire ASM bundles of each airway was counted manually. The basal 
membrane length (Pi) was traced manually and used to correct the previously described variables for variation in 
airway size25. ASM bundle composition (fraction occupied by myocytes or ECM) was assessed by point counting, 
each point corresponding to an area of 88 μm2. ASM cell size was indirectly calculated (ASM area x ASM myocyte 
fraction/myocyte nuclei). In EBBs, ASM area, ASM composition, ASM cell size, and lamina propria thickness 
(epithelium-to-ASM distance) were assessed as previously described19.
Statistical analysis. Statistical analysis was performed with SAS v.9.3 (Cary, NC, USA). Studies I and 
II were analyzed separately as 7 horses participated in both studies. Data distribution was assessed using the 
Kolmogorov–Smirnov test. Data not normally distributed were log 10 transformed. Unless otherwise stated, data 
are expressed as mean ± S.D. A repeated-measures linear model was employed with “time” as within-subject fac-
tor, “treatment” as a between-subjects factor. A priori contrasts with Benjamini-Hochberg correction were used 
for testing differences among groups and times (all time-points vs. baseline). “Disease severity” was defined based 
on RL values. Horses presenting episodes of airflow obstruction with RL > 3 cmH2O/L/s prior or during the study 
period were allocated to the group with increased disease severity. The relationship between disease severity and 
remodelling was assessed only at baseline to avoid cross-over effects with treatments. Paired t-test was used for 
analysis of residual bronchoconstriction after bronchodilator administration and peripheral ASM mass. A linear 
mixed model with “subject” as random-effect was used for studying associations between different parameters. 
Depending on data distribution, Spearman or Pearson test was used for correlations.
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
References
 1. Bergeron, C., Tulic, M. K. & Hamid, Q. Airway remodelling in asthma: from benchside to clinical practice. Can Respir J 17, e85–93 
(2010).
 2. Grainge, C. L. et al. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 364, 2006–2015, doi:10.1056/
NEJMoa1014350 (2011).
 3. James, A. L. et al. Airway smooth muscle thickness in asthma is related to severity but not duration of asthma. Eur Respir J 34, 
1040–1045 (2009).
 4. James, A. L. et al. Airway smooth muscle hypertrophy and hyperplasia in asthma. Am J Respir Crit Care Med 185, 1058–1064, 
doi:10.1164/rccm.201110-1849OC (2012).
 5. Lambert, R. K., Wiggs, B. R., Kuwano, K., Hogg, J. C. & Pare, P. D. Functional significance of increased airway smooth muscle in 
asthma and COPD. J Appl Physiol 74, 2771–2781 (1993).
 6. Poon, A. H., Eidelman, D. H., Martin, J. G., Laprise, C. & Hamid, Q. Pathogenesis of severe asthma. Clin Exp Allergy 42, 625–637, 
doi:10.1111/j.1365-2222.2012.03983.x (2012).
 7. Woodruff, P. G. & Innes, A. L. Quantitative morphology using bronchial biopsies. Eur Respir Rev 15, 157–161, 
doi:10.1183/09059180.00010106 (2006).
 8. Carroll, N., Elliot, J., Morton, A. & James, A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 
147, 405–410 (1993).
 9. Manoharan, A., Anderson, W. J., Lipworth, J., Ibrahim, I. & Lipworth, B. J. Small airway dysfunction is associated with poorer 
asthma control. Eur Respir J 44, 1353–1355, doi:10.1183/09031936.00082314 (2014).
 10. Farah, C. S. et al. Association between peripheral airway function and neutrophilic inflammation in asthma. Respirology 20, 
975–981, doi:10.1111/resp.12550 (2015).
 11. Black, J. L., Oliver, B. G. & Roth, M. Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting 
beta-agonists. Chest 136, 1095–1100, doi:10.1378/chest.09-0354 (2009).
 12. GINA Guidelines, Global Strategy for Asthma Management and Prevention, (2016).
 13. Anderson, W. J., Zajda, E. & Lipworth, B. J. Are we overlooking persistent small airways dysfunction in community-managed 
asthma? Ann Allergy Asthma Immunol 109, 185–189 e182, doi:10.1016/j.anai.2012.06.022 (2012).
 14. Bergeron, C. et al. Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of 
hydrofluoroalkane-flunisolide. J Allergy Clin Immunol 116, 983–989, doi:10.1016/j.jaci.2005.07.029 (2005).
 15. Postma, D. S. et al. Unmet needs for the assessment of small airways dysfunction in asthma: introduction to the ATLANTIS study. 
Eur Respir J 45, 1534–1538, doi:10.1183/09031936.00214314 (2015).
 16. Balzar, S., Wenzel, S. E. & Chu, H. W. Transbronchial biopsy as a tool to evaluate small airways in asthma. Eur Respir J 20, 254–259 
(2002).
 17. Leclere, M., Lavoie-Lamoureux, A. & Lavoie, J. P. Heaves, an asthma-like disease of horses. Respirology 16, 1027–1046, doi:10.1111/
j.1440-1843.2011.02033.x (2011).
 18. Bullone, M., Godbout, M., Martin, G. J. & Lavoie, J. P. Endobronchial ultrasonography of isolated bronchi reveals increased airway 
smooth muscle mass in large airways of asthmatic horses. Am J Respir Crit Care Med 189, A2382 (2014).
www.nature.com/scientificreports/
1 2Scientific REPoRTs | 7: 8843  | DOI:10.1038/s41598-017-09414-8
 19. Bullone, M., Chevigny, M., Allano, M., Martin, J. G. & Lavoie, J. P. Technical and physiological determinants of airway smooth 
muscle mass in endobronchial biopsy samples of asthmatic horses. J Appl Physiol (1985) 117, 806–815, doi:10.1152/
japplphysiol.00468.2014 (2014).
 20. Leclere, M., Bedard, C., Cortes-Dubly, M. L. & Lavoie, J. P. Blood hypercoagulability and systemic inflammation in horses with 
heaves. Veterinary Journal 206, 105–107, doi:10.1016/j.tvjl.2015.04.012 (2015).
 21. Abraham, G., Brodde, O. E. & Ungemach, F. R. Regulation of equine lymphocyte beta-adrenoceptors under the influence of 
clenbuterol and dexamethasone. Equine Vet J 34, 587–593 (2002).
 22. Herszberg, B., Ramos-Barbon, D., Tamaoka, M., Martin, J. G. & Lavoie, J. P. Heaves, an asthma-like equine disease, involves airway 
smooth muscle remodeling. J Allergy Clin Immunol 118, 382–388, doi:10.1016/j.jaci.2006.03.044 (2006).
 23. Leclere, M. et al. Effect of antigenic exposure on airway smooth muscle remodeling in an equine model of chronic asthma. Am J 
Respir Cell Mol Biol 45, 181–187, doi:10.1165/rcmb.2010-0300OC (2011).
 24. Leclere, M. et al. Corticosteroids and Antigen Avoidance Decrease Airway Smooth Muscle Mass in an Equine Asthma Model. Am J 
Respir Cell Mol Biol, 589–596, doi:10.1165/rcmb.2011-0363OC (2012).
 25. Bullone, M., Beauchamp, G., Godbout, M., Martin, J. G. & Lavoie, J. P. Endobronchial Ultrasound Reliably Quantifies Airway 
Smooth Muscle Remodeling in an Equine Asthma Model. PLoS One 10, e0136284, doi:10.1371/journal.pone.0136284 (2015).
 26. Reid, D. W. et al. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. 
Eur Respir J 21, 994–999 (2003).
 27. Jeffery, P. K. et al. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 20, 1378–1385 
(2002).
 28. Maneechotesuwan, K. et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 128, 1936–1942, doi:10.1378/
chest.128.4.1936 (2005).
 29. Monteseirin, J. Neutrophils and asthma. J Investig Allergol Clin Immunol 19, 340–354 (2009).
 30. Holgate, S. T. et al. Epithelial-mesenchymal communication in the pathogenesis of chronic asthma. Proc Am Thorac Soc 1, 93–98, 
doi:10.1513/pats.2306034 (2004).
 31. Chernyavsky, I. L. et al. The role of inflammation resolution speed in airway smooth muscle mass accumulation in asthma: insight 
from a theoretical model. PLoS One 9, e90162, doi:10.1371/journal.pone.0090162 (2014).
 32. Hamid, Q. et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 100, 44–51 (1997).
 33. Wenzel, S. E. et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. 
Am J Respir Crit Care Med 156, 737–743, doi:10.1164/ajrccm.156.3.9610046 (1997).
 34. Roth, M. et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through 
synchronised cellular signalling. Lancet 360, 1293–1299, doi:10.1016/S0140-6736(02)11319-5 (2002).
 35. Yick, C. Y. et al. Glucocorticoid-induced changes in gene expression of airway smooth muscle in patients with asthma. Am J Respir 
Crit Care Med 187, 1076–1084, doi:10.1164/rccm.201210-1886OC (2013).
 36. Chevigny, M., Guerin-Montpetit, K., Vargas, A., Lefebvre-Lavoie, J. & Lavoie, J. P. Contribution of SRF, Elk-1, and myocardin to 
airway smooth muscle remodeling in heaves, an asthma-like disease of horses. Am J Physiol Lung Cell Mol Physiol 309, L37–45, 
doi:10.1152/ajplung.00050.2015 (2015).
 37. Vargas, A., Roux-Dalvai, F., Droit, A. & Lavoie, J. P. Neutrophil-Derived Exosomes: A New Mechanism Contributing to Airway 
Smooth Muscle Remodeling. Am J Respir Cell Mol Biol 55, 450–461, doi:10.1165/rcmb.2016-0033OC (2016).
 38. Qian, C. J., Coulombe, J., Suissa, S. & Ernst, P. Pneumonia risk in asthma patients using inhaled corticosteroids: a quasi-cohort study. 
Br J Clin Pharmacol, doi:10.1111/bcp.13295 (2017).
 39. Manuyakorn, W. et al. Mechanical Strain Causes Adaptive Change in Bronchial Fibroblasts Enhancing Profibrotic and Inflammatory 
Responses. PLoS One 11, e0153926, doi:10.1371/journal.pone.0153926 (2016).
 40. Kotaru, C. et al. Regional fibroblast heterogeneity in the lung: implications for remodeling. Am J Respir Crit Care Med 173, 
1208–1215, doi:10.1164/rccm.200508-1218OC (2006).
 41. Chakir, J. et al. Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, 
and type I and type III collagen expression. J Allergy Clin Immunol 111, 1293–1298 (2003).
 42. Bosse, Y., Riesenfeld, E. P., Pare, P. D. & Irvin, C. G. It’s not all smooth muscle: non-smooth-muscle elements in control of resistance 
to airflow. Annu Rev Physiol 72, 437–462, doi:10.1146/annurev-physiol-021909-135851 (2010).
 43. Araujo, B. B. et al. Extracellular matrix components and regulators in the airway smooth muscle in asthma. Eur Respir J 32, 61–69, 
doi:10.1183/09031936.00147807 (2008).
 44. Yick, C. Y. et al. Extracellular matrix in airway smooth muscle is associated with dynamics of airway function in asthma. Allergy 67, 
552–559, doi:10.1111/j.1398-9995.2011.02773.x (2012).
 45. Nihlberg, K. et al. Altered matrix production in the distal airways of individuals with asthma. Thorax 65, 670–676, doi:10.1136/
thx.2009.129320 (2010).
 46. Pini, L. et al. Differences in proteoglycan deposition in the airways of moderate and severe asthmatics. Eur Respir J 29, 71–77, 
doi:10.1183/09031936.00047905 (2007).
 47. Lambers, C. et al. Extracellular matrix composition is modified by beta(2)-agonists through cAMP in COPD. Biochem Pharmacol 
91, 400–408, doi:10.1016/j.bcp.2014.07.026 (2014).
 48. Lamyel, F. et al. The beta2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts. Naunyn 
Schmiedebergs Arch Pharmacol 384, 133–145, doi:10.1007/s00210-011-0655-5 (2011).
 49. Levenson, M. Long-acting beta-agonists and adverse asthma events meta-analysis statistical briefing package for joint meeting of 
the pulmonary-allergy drugs advisory committee, drug safety and risk management advisory committee and pediatric advisory 
committee on December 10–11, 2008. Quantitative safety and pharmacoepidemiology group, United States Food and Drug 
Administration. (2008).
 50. Boulet, L. P. et al. Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of 
inhaled corticosteroids. Eur Respir J 11, 1091–1097 (1998).
 51. Cheung, D. et al. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in 
patients with mild asthma. N Engl J Med 327, 1198–1203, doi:10.1056/NEJM199210223271703 (1992).
 52. Knight, J. M. et al. Long-Acting Beta Agonists Enhance Allergic Airway Disease. PLoS One 10, e0142212, doi:10.1371/journal.
pone.0142212 (2015).
 53. Kamachi, A. et al. Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic 
asthma. Thorax 56, 19–24 (2001).
 54. Riesenfeld, E. P. et al. Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease. 
Respir Res 11, 22, doi:10.1186/1465-9921-11-22 (2010).
 55. Bai, T. R., Vonk, J. M., Postma, D. S. & Boezen, H. M. Severe exacerbations predict excess lung function decline in asthma. Eur Respir 
J 30, 452–456, doi:10.1183/09031936.00165106 (2007).
 56. O’Byrne, P. M. et al. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 179, 19–24, doi:10.1164/
rccm.200807-1126OC (2009).
 57. Ogawa, H., Fujimura, M., Takeuchi, Y. & Makimura, K. Impact of Schizophyllum sensitization on decline of lung function in 
asthma. J Asthma 50, 764–768, doi:10.3109/02770903.2013.803573 (2013).
www.nature.com/scientificreports/
13Scientific REPoRTs | 7: 8843  | DOI:10.1038/s41598-017-09414-8
 58. Dijkstra, A. et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax 61, 105–110, 
doi:10.1136/thx.2004.039271 (2006).
 59. Lange, P., Scharling, H., Ulrik, C. S. & Vestbo, J. Inhaled corticosteroids and decline of lung function in community residents with 
asthma. Thorax 61, 100–104, doi:10.1136/thx.2004.037978 (2006).
 60. Henrikson, S. L. & Rush, B. R. Efficacy of salmeterol xinafoate in horses with recurrent airway obstruction. J Am Vet Med Assoc 218, 
1961–1965 (2001).
 61. Jean, D., Vrins, A. & Lavoie, J. P. Monthly, daily, and circadian variations of measurements of pulmonary mechanics in horses with 
chronic obstructive pulmonary disease. Am J Vet Res 60, 1341–1346 (1999).
 62. Derksen, F. J. et al. Aerosolized albuterol sulfate used as a bronchodilator in horses with recurrent airway obstruction. Am J Vet Res 
60, 689–693 (1999).
 63. Couetil, L. et al. Effects of N-butylscopolammonium bromide on lung function in horses with recurrent airway obstruction. J Vet 
Intern Med 26, 1433–1438, doi:10.1111/j.1939-1676.2012.00992.x (2012).
 64. Jean, D., Vrins, A., Beauchamp, G. & Lavoie, J. P. Evaluation of variations in bronchoalveolar lavage fluid in horses with recurrent 
airway obstruction. Am J Vet Res 72, 838–842, doi:10.2460/ajvr.72.6.838 (2011).
 65. Lugo, J. et al. Safety and efficacy of a technique for thoracoscopically guided pulmonary wedge resection in horses. Am J Vet Res 63, 
1232–1240 (2002).
 66. Relave, F. et al. Thoracoscopic lung biopsies in heaves-affected horses using a bipolar tissue sealing system. Vet Surg 39, 839–846, 
doi:10.1111/j.1532-950X.2010.00720.x (2010).
 67. Russell, H. K. Jr. A modification of Movat’s pentachrome stain. Arch Pathol 94, 187–191 (1972).
Acknowledgements
This study would not have been possible without the precious technical help as well as intellectual support of 
Roxane Boivin, Mylène Chevigny, Roger Fontaine, Mohamed Issouf, Geneviève Michaud, and Catheryna Ouimet 
(listed in alphabetical order).This study was funded by the Canadian Institutes of Health Research (MOP-
102751), Canadian Foundation for Innovation (#29172), PBEEE-V1 scholarship from the FRQNT (#176872, 
Fonds de Recherche du Québec - Nature et Technologies). The corresponding author had full access to all study 
data and had final responsibility for the decision to submit for publication.
Author Contributions
M.B., J.P.L. and J.G.M. conceived the study. M.B., A.V. and Y.E. performed the experiments. M.B. wrote the 
manuscript. All authors revised and accepted the final version of the manuscript.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-09414-8
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
